Clinical trial · Observational
Breast Tumour Size Measurement by Field Cycling Imaging
NCT07492043CI-TRIAL-00106414BREVIAnot yet recruitingClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The goal of this study is to test if a new type of MRI scanner, called Field-Cycling Imaging (FCI), can accurately estimate tumour size in patients with a type of breast cancer called ductal carcinoma in situ (DCIS). The main question it aims to answer is: Can FCI accurately estimate DCIS lesion size compared with histology results? Participants will have a standard MRI scan and an FCI scan before undergoing surgery to remove the tumour.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Breast Cancer | Malignant Breast Neoplasm | CURATED_EXACT | 0.92 |
| Ductal Carcinoma In Situ | Breast Ductal Carcinoma In Situ | ALIAS | 0.90 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| 3T MRI research scan | Other | — | UNRESOLVED |
| Field-Cycling Imaging research scan | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Breast Cancer
- description
- Participants with breast cancer of ductal carcinoma in-situ (DCIS) who are due to undergo surgical treatment.
- interventionNames
- Other: Field-Cycling Imaging research scan
- Other: 3T MRI research scan
Primary outcomes (1)
- measure
- Accuracy of DCIS lesion size estimation using FCI, validated against histopathological measurements (gold standard).
- timeFrame
- Baseline
- description
- Extent of agreement between lesion size estimation by FCI and actual lesion size according to NHS histopathology results.
Secondary outcomes (1)
- measure
- Comparison of DCIS lesion measurements using FCI and 3T MRI.
- timeFrame
- Baseline
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Females ≥ 18 years old. * Subjects diagnosed with DCIS on initial biopsy. * Lesion size \>1 cm on imaging. * Subjects undergoing surgery as part of their treatment. * Able to fit comfortably in the scanners. * Able to understand written and spoken English. Exclusion Criteria: * Subjects undergoing chemotherapy or hormonal therapy. * Individuals unable to give informed consent. * Contra-indications to MRI scanning such as implantable cardiac devices. * Known allergy to contrast agent.
References
Publications (1)
- BACKGROUNDMallikourti V, Ross PJ, Maier O, Hanna K, Husain E, Davies GR, Lurie DJ, Lip G, Lahrech H, Masannat Y, Broche LM. Field cycling imaging to characterise breast cancer at low and ultra-low magnetic fields below 0.2 T. Commun Med (Lond). 2024 Oct 30;4(1):221. doi: 10.1038/s43856-024-00644-2. PMID 39478081